Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2020-08-09 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
首次公开发行股票并在科创板上市发行安排及初步询价公告
Regulatory Filings
2020-08-09 Chinese
首次公开发行股票并在科创板上市招股意向书
Capital/Financing Update Classification · 95% confidence The document is a 招股意向书 (Prospectus or Offering Intention Document) for an initial public offering (IPO) on the Shanghai Stock Exchange STAR Market (科创板). It contains detailed information about the company's business, financial data, risk factors, management, legal matters, and other disclosures typical of an IPO prospectus. It includes audited financial information, risk disclosures, and detailed company background. This type of document is not an earnings release, annual report, or interim report, but rather a detailed offering document for a new stock issuance. The closest fitting category in the provided list is 'Capital/Financing Update (CAP)' which covers updates on company fundraising and financing activities, including IPO prospectuses. The document is lengthy (15,000 characters) and contains substantive financial and business information, not just an announcement or summary. Therefore, the correct classification is CAP with high confidence.
2020-08-09 Chinese
首次公开发行股票并在科创板上市招股意向书附录
Regulatory Filings
2020-08-09 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.